LUSINE APIKYAN: Open Payments
NPI 1497176705 · LOS ANGELES, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$229 in 10 payments from 7 companies in 2025. Trend: 2023 $507 · 2024 $433 · 2025 $229
Food & beverage: $229
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 2 | $61 |
| Amgen Inc. | 3 | $47 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Lilly USA, LLC | 1 | $26 |
| PFIZER INC. | 1 | $25 |
| DePuy Synthes Sales Inc. | 1 | $21 |
| ABBVIE INC. | 1 | $20 |
Products named: OTEZLA, Wegovy, Rybelsus, ZENPEP, ZEPBOUND, ZAVZPRET, EMBOTRAP, QULIPTA.
Industry payments across CA — which companies pay providers there.
